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Atrial fibrillation (AF) affects over 33 million individuals worldwide1 and has a complex 
heritability.2 We conducted the largest meta-analysis of genome-wide association studies 
for AF to date, consisting of over half a million individuals including 65,446 with AF. In 
total, we identified 97 loci significantly associated with AF including 67 of which were 
novel in a combined-ancestry analysis, and 3 in a European specific analysis. We sought 
to identify AF-associated genes at the GWAS loci by performing RNA-sequencing and 
expression quantitative trait loci (eQTL) analyses in 101 left atrial samples, the most 
relevant tissue for AF. We also performed transcriptome-wide analyses that identified 57 
AF-associated genes, 42 of which overlap with GWAS loci. The identified loci implicate 
genes enriched within cardiac developmental, electrophysiological, contractile and 
structural pathways. These results extend our understanding of the biological pathways 
underlying AF and may facilitate the development of therapeutics for AF.  
 
Atrial fibrillation (AF) is the most common heart rhythm disorder, and is a leading cause of heart 
failure and stroke.3 Prior genome-wide association studies (GWAS) have identified at least 30 
loci associated with AF.4–9 We conducted a large-scale analysis with over half a million 
participants, including 65,446 with AF, from more than 50 studies. Our AF sample was 
composed of 84.2% European, 12.5% Japanese, 2% African American, and 1.3% Brazilian and 
Hispanic populations (Supplementary Table 1). We used the Haplotype Reference Consortium 
(HRC) reference panel to impute variants from SNP array data for 75% of the samples (Figure 
1). In the remainder, we included HRC overlapping variants from 1000 Genomes imputed data, 
or from a combined reference panel. We analyzed 8,328,530 common variants (minor allele 
frequency (MAF) >5%), 2,884,670 low frequency variants (1%> MAF ≥5%), and 936,779 rare 
variants (MAF ≤1%). 
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The combined-ancestry meta-analysis revealed 94 AF-associated loci, 67 of which were 
novel at genome-wide significance (P-value (P) < 1x10-8). This conservative threshold accounts 
for testing independent variants with MAF ≥0.1% using a Bonferroni correction, while use of a 
more commonly utilized threshold of 5x10-8 resulted in the identification of an additional 10 loci 
(Supplementary Table 2). The majority of sentinel variants (n=92) were common (MAF >5%), 
with relative risks ranging from 1.04 to 1.55. Two low frequency sentinel variants were identified 
within the genes C1orf185 and UBE4B (Figure 2, Table 1, Supplementary Table 3, 
Supplementary Figure 1).  
 
We then conducted a gene set enrichment analysis with the results from the combined-
ancestry meta-analysis using MAGENTA. We identified 55 enriched gene sets or pathways that 
largely fall into cardiac developmental, electrophysiological, and cardiomyocyte contractile or 
structural functional groups (Supplementary Table 4). In total, 48 of the 67 novel loci contain 
one or more genes within 500kb of the sentinel variant that were part of an enriched gene set or 
pathway (Supplementary Figure 2).  
 
Next, we performed ancestry-specific meta-analyses. Among individuals of European 
ancestry, we identified 3 additional loci associated with AF, each of which had a sub-threshold 
association (P < 1x10-6) in the combined-ancestry meta-analysis. These loci were located close 
to or within the genes CDK6, EPHA3, and GOSR2 (Supplementary Table 5, Supplementary 
Figure 3-4). The region most significantly associated with AF in Europeans, Japanese, and 
African Americans (Supplementary Figure 5-6) was on chromosome 4q25, upstream of the 
gene PITX2 (Supplementary Figure 7). We did not observe significant heterogeneity of effect 
estimates across ancestries for most associations, suggesting that top genetic susceptibility 
signals for AF have a relatively constant effect across ancestries (Table 1, Supplementary 
Table 3, Supplementary Figure 8). The proportion of heritability explained by the loci from the 
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European ancestry analysis was 42%, compared to previously reported 25%10 (Supplementary 
Table 6). 
 
In conditional and joint analyses of the European ancestry results, we found 11 loci with 
multiple, independent AF-associated signals. At a locus centered on a cluster of sodium channel 
genes, we identified 3 regions that independently associate with AF within SCN10A, SCN5A 
and a third signal between both genes. At the previously described TBX5 locus,8 we detected a 
novel independent signal close to TBX3. Pairwise linkage disequilibrium (LD) estimates 
between the independent variants at both loci were extremely low (r2 <0.03; Supplementary 
Table 7). 
 
For 13 AF loci, the sentinel variant or a proxy (r2 >0.6) was a missense variant. A missense 
variant (rs11057401) in CCDC92 was predicted to be damaging by 4 of 5 in silico prediction 
algorithms (Supplementary Table 8); and was previously associated with coronary artery 
disease.11 Since most AF-associated variants reside in non-coding regions we sought to 
determine if the sentinel variants or their proxies (r2 >0.6) fell within regulatory regions in heart 
tissues based on chromatin states from the Roadmap Epigenomics Consortium. At 64 out of 67 
novel loci, variants were located within regulatory elements (Supplementary Table 9); AF-
associated loci were also significantly enriched within regulatory elements (Supplementary 
Figure 9).  
 
We then sought to link risk variants to candidate genes by assessing their effect on gene 
expression levels. First, since AF often arises from the pulmonary veins and left atrium (LA), we 
performed RNA sequencing, genotyping, and eQTL analyses in 101 human left atrial samples 
without structural heart disease from the Myocardial Applied Genomics Network repository. 
Second, we identified eQTLs from right atrial (RA) and left ventricular (LV) cardiac tissue from 
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the Genotype Tissue Expression (GTEx) project. Finally, we performed a transcriptome-wide 
analysis using the MetaXcan12 method, which infers the association between genetically 
predicted gene expression and disease risk.  
 
We observed eQTLs to one or more genes at 17 novel loci. Of the 10 eQTLs detected in LA 
tissue 8 were also detected in RA or LV, with consistent directionality. For example, we 
observed that rs4484922 was an eQTL for CASQ2 in LA tissue only. Although we detected 
more AF loci with eQTLs in the RA or LV data, for many of these (n=8) the results pointed to 
multiple genes per locus (Supplementary Table 10-12). LA eQTL studies may facilitate the 
prioritization of candidate genes, but are currently limited by sample size. 
 
For the transcriptome-wide analyses we used GTEx human atrial and ventricular expression 
data as a reference. We identified 57 genes significantly associated with AF. Of these, 42 genes 
were located at AF loci, whereas the remaining 15 were >500kb from an AF sentinel variant 
(Supplementary Table 13, Figure 3). The probable candidate genes at each locus are 
summarized in Supplementary Table 12. For example, at the locus with lead variant 
rs4484922 we observed results from all downstream analyses pointing towards the nearest 
gene CASQ2, at rs12908437 towards the gene IGFR1, and at rs113819537 towards the gene 
SSPN. However, for many loci the evaluation of candidate genes remains challenging. 
 
We then sought to assess the pleiotropic effects of the identified AF risk variants. First, we 
queried the NHGRI-EBI GWAS Catalog to detect associations to other phenotypes 
(Supplementary Table 14). Second, using the UK Biobank,13 we performed a phenome-wide 
association study (pheWAS) for 12 AF risk factors (Supplementary Table 15). As illustrated in 
Figure 4, distinct clusters of variants were associated with AF as well as height, BMI, and 
hypertension. For example, we observed a pleiotropic effect at rs880315 (CASZ1) for blood 
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pressure14 and hypertension14, that was also observed in the UK Biobank (association with 
hypertension, P = 2.56x10-34).  
 
In sum, we identified a total of 97 distinct AF loci from 65,446 AF cases and more than 
522,000 referents. In recent pre-publication results, Nielsen et al., reported 111 loci from 60,620 
AF cases and more than 970,000 referents,15 including more than 18,000 AF cases from our 
prior report.8 We therefore performed a preliminary meta-analysis for the top loci in non-
overlapping participants from these two large efforts with a resulting total of over 93,000 AF 
cases and more than 1 million referents. In aggregate, we identified at least 134 distinct AF-
associated loci (Supplementary Table 16). 
 
Four major themes emerge from the identified AF loci. First, two AF loci contain genes that 
are primary targets for current antiarrhythmic medications used to treat AF. The SCN5A gene 
encodes a sodium channel in the heart, the target of sodium-channel-blockers such as 
flecainide and propafenone. Similarly, KCNH2 encodes the alpha subunit of the potassium 
channel complex, the target of potassium-channel-inhibiting medications such as amiodarone, 
sotalol, and dofetilide. SCN5A and KCNH2 have previously been implicated in AF through 
GWAS,8 candidate gene analysis16 and family-based studies.17,18 
 
Second, transcriptional regulation appears to be a key feature of AF etiology. TBX3 and the 
adjacent gene TBX5 encode transcription factors, that have been shown to regulate the 
development of the cardiac conduction system.19 Similarly, the NKX2-5 encodes a transcription 
factor, that is an early cue for cardiac development and has been associated with congenital 
heart disease20 and heart rate21 (Supplementary Table 14). Further, reduced function of the 
transcription factor encoded by PITX2 has been associated with AF, shortening of the left atrial 
action potential, and with modulation of sodium channel blocker therapy in the adult left 
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atrium.22–24 A transcriptional co-regulatory network governed by transcription factors encoded by 
TBX5 and PITX2 has been shown to be critical for atrial development.25  
 
Third, the transcriptome-wide analyses revealed a number of compelling findings. 
Decreased expression of PRRX1 associated with AF, a result consistent with findings where 
reduction of PRRX1 in zebrafish and stem cell-derived cardiomyocytes was associated with 
action potential shortening.26 Further, increased expression of TBX5 and KCNJ5 was 
associated with AF, a finding consistent with gain-of-function mutations in TBX5 reported in a 
family with Holt-Oram syndrome and a high penetrance of AF.27 Similarly, KCNJ5 encodes a 
potassium channel that underlies a component of the IKAch current, a channel that is upregulated 
in AF. Thus, prior studies support both the role of PRRX1, TBX5, and KCNJ5 in AF and the 
observed directionality. 
 
Fourth, many of the novel loci implicate genes that underlie Mendelian forms of arrhythmia 
syndromes. Mutations in CASQ2 lead to catecholaminergic polymorphic ventricular 
tachycardia.28,29 Pathogenic variants in PKP2 impair cardiomyocyte communication and 
structural integrity, and are a common cause of arrhythmogenic right ventricular 
cardiomyopathy.30,31 Mutations in GJA5, KCNH2, SCN5A, KCNJ2, MYH7, NKX2-5, have been 
mapped in a variety of inherited arrhythmia, cardiomyopathy, or conduction system diseases.32 
Our observations highlight the pleiotropy of variation in genes specifying cardiac conduction, 
morphology, and function, and underscore the complex, polygenic nature of AF. 
 
In conclusion, we conducted the largest AF meta-analysis to date and report a more than 
three-fold increase in the number of loci associated with this common arrhythmia. Our results 
lay the groundwork for functional evaluations of genes implicated by AF risk loci. Our findings 
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also broaden our understanding of biological pathways involved in AF and may facilitate the 
development of therapeutics for AF. 
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Figure legends 
Figure 1. Study and analysis flowchart 
Top, overview of the participating studies, number of AF cases and referents, and the percent of 
samples imputed with each reference panel. Middle, summary of the primary analyses and the 
newly discovered loci for AF. Bottom, overview of the secondary analyses to evaluate AF risk 
variants and loci.  
 
Figure 2. Manhattan plot of combined-ancestry meta-analysis 
The plot shows 67 novel (red) and 27 known (blue) genetic loci associated with AF at a 
significance level of P < 1x10-8 (dashed line), for the combined-ancestry meta-analysis 
(n=588,190). The significance level accounts for multiple testing of independent variants with 
MAF ≥0.1% using a Bonferroni correction. P-values (two-sided) were derived from a meta-
analysis using a fixed effects model with an inverse-variance weighted approach. The y-axis 
has a break between –log10(P) of 30 and 510 to emphasize the novel loci 
 
Figure 3. Volcano plot of transcriptome-wide analysis from human heart tissues 
The plots show the results from the transcriptome-wide analysis based on left ventricle (a, 
n=190) and right atrial appendage (b, n=159) tissue from GTEx, calculated with the MetaXcan 
method based on the combined-ancestry summary level results (n=588,190). Each plotted point 
represents the association results for an individual gene. The x-axis shows the effect size for 
associations of predicted gene expression and AF risk for each tested gene. The y-axis shows 
the –log10(P) for the associations per gene. Genes with positive effect (red) showed an 
association of increased predicted gene expression with AF risk. Genes with negative effect 
(blue) showed an association of decreased predicted gene expression with AF risk. The 
highlighted genes are significant after Bonferroni correction for all tested genes and tissues with 
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a P-value < 5.36x10-6. The result for one gene for right atrial appendage (b) is not shown 
(SNX4, Effect = 6.94, P = 0.2). 
 
Figure 4. Cross-trait associations of AF risk variants with AF risk factors in the UK 
Biobank 
The heatmap shows associations of novel and known sentinel variants at AF risk loci from the 
combined-ancestry meta-analysis. Shown are variants and phenotypes with significant 
associations after correcting for 12 phenotypes via Bonferroni with P < 4.17x10-3. P-values (two-
sided) were derived from linear and logistic regression models. Listed next to each trait is the 
number of cases for binary traits or total sample size for quantitative traits. Hierarchical 
clustering was performed on a variant level using the complete linkage method based on 
Euclidian distance. Coloring represents Z-scores for each respective trait or disease, oriented 
toward the AF risk allele. Red indicates an increase in the trait or disease risk while blue 
indicates a decrease in the trait or disease risk. Abbreviations, BMI, body-mass index, CAD, 
coronary artery disease, PVD, pulmonary vascular disease. 
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Online Methods 
Samples 
Participants from more than 50 studies were included in this analysis. Participants were 
collected from both case-control studies for atrial fibrillation (AF) and population based studies. 
The majority of studies were part of the Atrial Fibrillation Genetics (AFGen) consortium and the 
Broad AF Study (Broad AF). Additional summary level results from the UK Biobank (UKBB) and 
the Biobank Japan (BBJ) were included (Figure 1). Cases include participants with paroxysmal 
or permanent atrial fibrillation, or atrial flutter, and referents were free of these diagnoses. 
Adjudication of atrial fibrillation for each study is described in the Supplementary Notes. 
Ascertainment of AF in the UK Biobank includes samples with one or more of the following 
codes 1) Non-cancer illness code, self-reported (1471, 1483), 2) Operation code (1524), 3) 
Diagnoses – main/secondary ICD10 (I48, I48.0-4, I48.9), 4) Underlying (primary/secondary) 
cause of death: ICD10 (I48, I48.0-4, I48.9) 5) Diagnoses – main/secondary ICD9 (4273), 6) 
Operative procedures – main/secondary OPCS (K57.1, K62.1-4).8,10,33 Baseline characteristics 
for each study are reported in Supplementary Table 17. We analyzed: 55,114 cases and 
482,295 referents of European ancestry, 1,307 cases and 7,660 referents of African American 
ancestry, 8,180 cases and 28,612 referents of Japanese ancestry, 568 cases and 1,096 
referents from Brazil and 277 cases and 3,081 referents of Hispanic ethnicity. Samples from the 
UK Biobank, the Broad AF Study, and the following studies from the AFGen consortium: SiGN, 
EGCUT, PHB and the Vanderbilt Atrial Fibrillation Registry, were previously not included in 
primary AF GWAS discovery analyses. There is minimal sample overlap from the studies MGH 
AF, BBJ and AFLMU between this and previous analyses. Ethics approval for participation was 
obtained individually by each study. All relevant ethical regulations were followed for this work. 
Written informed consent was obtained from all study participants. 
The Institutional Review Board (IRB) at Massachusetts General Hospital reviewed and 
approved the overall study.  
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Genotyping and Genotype Calling 
Samples within the Broad AF Study were genotyped at the Broad Institute using the Infinium 
PsychArray-24 v1.2 Bead Chip. They were genotyped in 19 batches, grouped by origin of the 
samples and with a balanced case control mix on each array. Common variants (≥1% MAF) 
were called with GenomeStudio v1.6.2.2 and Birdseed v1.33,34 while rare variants (<1% MAF) 
were called with zCall.35 Batch specific quality control (QC) was performed on each call-set 
including >95% sample call rate, Hardy-Weinberg-Equilibrium (HWE) P > 1x10-6 and variant 
call-rate >97%. For common variants, a consensus merge was performed between the call-sets 
from GenomeStudio and Birdseed. For each genotype only concordant calls between the two 
algorithms were kept. The common variants from the consensus call were then combined with 
the rare variants calls from the zCall algorithm. Samples from all batches were joined prior to 
performing pre-imputation QC steps. Detailed procedures for genotyping and genotype calling 
for the SiGN study,36 the UK Biobank,37,38 and the Biobank Japan9 are described elsewhere. 
Details on genotyping and calling for all participating studies are listed in Supplementary Table 
18. 
 
Imputation 
Pre-imputation QC filtering of samples and variants was conducted based on recommended 
guidelines as described in Supplementary Table 19. QC steps were performed by each study 
and are described in Supplementary Table 18. Most studies with European ancestry samples 
performed imputation with the HRC reference v1.139 panel on the Michigan Imputation Server 
v1.0.1.40 Studies without available HRC imputation were included based on imputation to the 
1000 Genomes Phase 1 integrated v3 panel (March 2012).41 Participants of the SiGN study 
were imputed to a combined reference panel consisting of 1000 Genomes phase 1 plus 
Genome of the Netherlands.42 Studies from Brazil were imputed with the HRC reference v1.1 
panel. Studies of Japanese ancestry or Hispanic ethnicity were imputed to the 1000G Phase 1 
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integrated v3 panel (March 2012). Studies of African American ancestry were imputed to the 
HRC reference v1.1 panel or the 1000G Phase 1 integrated v3 panel (March 2012). Studies 
were advised to use the HRC preparation and checking tool 
(http://www.well.ox.ac.uk/~wrayner/tools/) prior to imputation. Prephasing and imputation 
methods for each study are described in Supplementary Table 18.  
 
Primary statistical analyses  
Genome-wide association testing on autosomal chromosomes was performed using an additive 
genetic effect model based on genotype probabilities. Each ancestry group was analyzed 
separately for each study. For the Broad AF Study, the primary statistical analysis was 
performed jointly on unrelated individuals, excluding one of each pair for related samples with 
PI_HAT >0.2 as calculated in PLINK v1.90.43,44 Samples with sex mismatches and sample call 
rate <97% were excluded. Ancestry groups were defined with ADMIXTURE45 based on 
genotyped, independent, and high quality variants, using the supervised method with 
1000Genomes phase 1 v3 samples as reference. A cutoff of 80% European ancestry was used 
to define the European subset and a cutoff of 60% African ancestry was used to define the 
African American subset. A Brazilian cohort within the Broad AF Study was analyzed 
separately. Principal components were calculated within each ancestry group with the smartpca 
program from EIGENSOFT v6.1.146. For the UK Biobank, a European subset was selected 
within samples with self-reported white race (British, Irish, or other) and similar genetic ancestry. 
Genetic similarity was defined with the aberrant47 package in R based on principal components, 
following the same method as described for the UK Biobank.38 We excluded samples with sex 
mismatches, outliers in heterozygosity and missing rates, samples that carry sex chromosome 
configurations other than XX or XY, and samples that were excluded from the kinship inference 
procedure as flagged in the UK Biobank QC file. We further removed one sample for each pair 
of third degree or closer relatives (kinship coefficient >0.0442), preferentially keeping samples 
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with AF case status. Primary analyses for all other studies were performed at the study sites 
and the summary level data of the results were provided. Prevalent cases were analyzed in a 
logistic regression model and most incident cases were analyzed in a Cox proportional hazards 
model. Studies with both prevalent and incident cases analyzed these either separately using a 
logistic regression model or Cox proportional hazards model respectively, or jointly in a logistic 
regression model. The following tools were used for primary GWAS: ProbABEL,48 SNPTEST,49 
FAST,50 mach2dat (http://www.sph.umich.edu/csg/yli), R,51 EPACTS 
(http://genome.sph.umich.edu/wiki/EPACTS), Hail (https://github.com/hail-is/hail) and PLINK44 
(Supplementary Table 18). Summary level results were filtered, keeping variants with 
imputation quality >0.3 and MAF * imputation quality * N events ≥10. Post-analysis QC steps of 
summary level results included a check of allele frequencies, inspection of Manhattan-plots, 
QQ-plots, PZ-plots, and the distribution of effect estimates and standard errors, calculation of 
genomic inflation (λGC), and consistent directionality for known AF risk variants.5  
 
Meta-analyses 
Summary level results were meta-analyzed jointly with METAL (released on 2011-03-25) using 
a fixed effects model with inverse-variance weighted approach, correcting for genomic control.52 
Separate meta-analyses were conducted for each ancestry. The results for the Japanese9 and 
Hispanic8 specific analyses have previously been reported and therefore their ancestry-specific 
results are not shown. Variants were included if they were present in at least two studies and 
showed an average MAF ≥0.1%. To correct for multiple testing, a genome-wide significance 
threshold of P < 1x10-8 was applied for each analysis. This threshold is based on a naive 
Bonferroni correction for independent variants with MAF ≥0.1%, using an LD threshold of r2 <0.8 
to estimate the number of independent variants based on European ancestry LD.53 As these 
meta-analyses are based on effect estimates and standard errors from both logistic regression 
and Cox proportional hazards regression, we report variant effects as relative risk, calculated as 
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the exponential of effect estimates. For sentinel variants reaching genome-wide significance in 
the combined ancestry meta-analysis, we assessed if effect estimates were homogeneous 
across ancestries by calculating an I2 statistic54 across ancestry specific meta-analyses. We 
account for multiple testing across 94 variants using a Bonferroni correction, resulting in a 
significance threshold of P < 5.32x10-4 for the heterogeneity test.  
 
Broad AF LD reference and proxies 
A linkage disequilibrium (LD) reference file was created including 26,796 European ancestry 
individuals from the Broad AF study. The LD reference was based on HRC imputed genotypes. 
Monomorphic variants and variants with imputation quality <0.1 were removed prior to 
conversion to hard calls. A genotype probability (GP) threshold filter of GP >0.8 was applied 
during hard call conversion. For multi-allelic sites the more common alleles were kept. Variants 
were included in the final reference file if the variant call rate was >70%.  
We identified proxies of sentinel variants as variants in LD of r2 >0.6 based on the Broad AF LD 
reference file, using PLINK v1.90.43,44  
 
Meta-analysis of provisional loci 
We meta-analyzed 111 variants from externally reported15 provisional loci within predominantly 
non-overlapping samples from the Broad AF Study, BBJ, EGCUT, PHB, SiGN and the 
Vanderbilt AF Registry with METAL (released on 2011-03-25).52 The predominantly non-
overlapping samples included a total of 32,957 AF cases and 83,546 referents, with minimal 
overlap from the studies MGH AF, BBJ and AFLMU. We subsequently meta-analyzed these 
results with the reported provisional results with METAL using a fixed effects model with 
inverse-variance weighted approach. We analyzed a total of 93,577 AF cases and 1,053,762 
referents. We compared our discovery results with the provisional loci using the same 
significance cutoff of P < 5x10-8 for both results. Overlapping loci were identified, if the reported 
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sentinel variants were located within 500kb of each other. For overlapping loci with differing 
sentinel variants we calculated the LD between the sentinel variants, based on the Broad AF LD 
reference panel of European ancestry. 
 
Variant consequence on protein coding sequence 
The most severe consequence for variants was identified with the Ensembl Variant Effect 
Predictor version 89.7 using RefSeq as gene reference and the option "pick" to identify one 
consequence per variant with the default pick order.55 We queried sentinel variants and their 
proxies to identify tagged variants with HIGH and MODERATE impact including the following 
consequences: "transcript_ablation", "splice_acceptor_variant", "splice_donor_variant", 
"stop_gained", "frameshift_variant", "stop_lost", "start_lost", "transcript_amplification", 
"inframe_insertion", "inframe_deletion", "missense_variant" and "protein_altering_variant". We 
evaluated each identified consequence on the protein coding sequence with in silico prediction 
tools to assess potentially damaging effects. The evaluation included MutationTaster56 (disease 
causing automatic or disease causing), SIFT57 (damaging), LRT58 (deleterious), Polyphen259 
prediction based on HumDiv and HumVar (probably damaging or possibly damaging). 
 
Chromatin states 
1) Chromatin state annotation. We identified chromatin states for sentinel variants and their 
proxies from the Roadmap Epigenomics Consortium 25-state model (2015)60 using HaploReg 
v4.61 We looked for chromatin states occurring in any included tissues as well as chromatin 
states occurring in heart tissue. Heart tissues include E065: Aorta, E083: Fetal Heart, E095: Left 
Ventricle, E104: Right Atrium and E105: Right Ventricle.  
2) Regulatory region enrichment. 1,000 sets of control loci were generated by matching SNPs 
to sentinel variants from the AF combined-ancestry analysis, with the SNPSnap62 tool. We used 
the European 1000 Genomes Phase 3 population to match via minor allele frequency, gene 
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density, distance to nearest gene and LD buddies using r2 >0.6 as LD cutoff and otherwise 
default settings. We excluded input SNPs and HLA SNPs from the matched SNPs. Loci were 
defined as SNPs and their proxies with r2 >0.6 based on LD from the European 1000 Genomes 
Phase 3 population. We identified SNPs in regulatory regions across all tissues and in cardiac 
tissues (E065, E095, E104, E105) based on the Roadmap Epigenomics Consortium 25-state 
model (2015)60 using HaploReg v4.61 Regulatory regions included the following states: 
2_PromU, 3_PromD1, 4_PromD2, 9_TxReg, 10_TxEnh5, 11_TxEnh3, 12_TxEnhW, 13_EnhA1, 
14_EnhA2, 15_EnhAF, 16_EnhW1, 17_EnhW2, 18_EnhAc, 19_DNase, 22_PromP and 
23_PromBiv. We calculated the percent overlap of each annotation per locus, defined as 
number of SNPs per locus that fall in regulatory regions divided by total number of SNPs per 
locus. Statistical significance was calculated with a permutation test from the perm package in 
R.63  
 
Expression quantitative trait loci (eQTL) 
Variants identified from GWAS were assessed for overlap with eQTLs from two sources: 
1) Left atrial (LA) tissue from the Myocardial Applied Genomics Network (MAGNet) 
repository. We performed RNA sequencing (RNA-seq) on 101 left atrial tissue samples from 
the MAGNet repository (http://www.med.upenn.edu/magnet/) on the Illumina HiSeq 4000 
platform at the Broad Institute Genomic Services. Left atrial tissue was obtained at the time of 
cardiac transplantation from normal donors with no evidence of structural heart disease. All left 
atrial samples were from individuals of European ancestry. A summary of the clinical 
characteristics for these samples is shown in Supplementary Table 20. Reads were aligned to 
the reference genome by STAR v2.4.1a64 and assigned to genes based on the GENCODE 
gene annotation.65 Gene expression was measured in fragments per kilobase of transcript per 
million mapped reads (FPKM) and subsequently quantile-normalized and adjusted for age, sex, 
and the first 10 principal components. Genotyping was performed on the Illumina 
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OmniExpressExome-8v1 array and imputed to the HRC reference panel. Principal components 
were calculated with the smartpca program from EIGENSOFT v6.1.146 and European ancestry 
was confirmed by assessing principal components in the samples combined with 1000 
Genomes European samples.41 Associations between gene expression and genotypes were 
tested in a linear regression model with QTLtools v1.0,66 in order to detect cis-eQTLs, defined 
as eQTLs within 1MB of the transcription start site of a gene. To account for multiple testing, an 
empirical false discovery rate (FDR) was used to identify significant eQTLs with a FDR <5%. 
2) Genotype-Tissue Expression (GTEx) project.67 We queried the GTEx version 6p database 
for cis-eQTLs with significant associations to gene expression levels in the two available heart 
tissues: left ventricle and right atrial appendage.68  
 
Association between predicted gene expression and risk of atrial fibrillation 
To investigate transcriptome-wide associations between predicted gene expression and AF 
disease risk, we employed the method MetaXcan v0.3.5.12 MetaXcan extends the previous 
method PrediXcan69 to predict the association between gene expression and a phenotype of 
interest, using summary association statistics. Gene expression prediction models were 
generated from eQTL datasets using Elastic-Net to identify the most predictive set of SNPs. 
Only models that significantly predict gene expression in the reference eQTL dataset (FDR 
<0.05) were considered. Pre-computed MetaXcan models for the two available heart tissues 
(left ventricle and right atrial appendage) in the genotype-tissue expression project version 6p 
(GTEx)68 were used to predict the association between gene expression and risk of AF. 
Summary level statistics from the combined ancestry meta-analysis were used as input. 4859 
genes were tested for left ventricle and 4467 genes were tested for right atrial appendage. 
Bonferroni correction was applied to account for the number of genes tested across both 
tissues, resulting in a significance threshold of P < 5.36x10-6, calculated as 0.05/(4859 + 4467). 
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Conditional and joint analyses 
Conditional and joint analyses70 of GWAS summary statistics were performed with Genome-
wide Complex Trait Analysis (GCTA v1.25.2)71 using a stepwise selection procedure to identify 
independently-associated variants on each chromosome. We used the Broad AF LD reference 
file for LD calculations.  
 
Gene set enrichment analysis (GSEA) 
A Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA) v2.472 was 
performed with a combined gene set input database 
(GO_PANTHER_INGENUITY_KEGG_REACTOME_BIOCARTA) based on publicly available 
data. The analysis was conducted using the summary level results from the combined ancestry 
meta-analysis. 4045 gene sets were included and multiple testing was corrected via false 
discovery rate (FDR). Gene sets were manually assigned to one or more of the following 
functional groups: developmental, electrophysiological, contractile/structural, and other. Genes 
within 500 kilobases of a sentinel variant were identified based on the longest spanning 
transcribed region in the RefSeq gene reference. For each gene set, genes close to significant 
loci were listed. The selected genes were assigned to one or more functional groups based on 
their affiliation to gene sets. Functional groups from gene sets with a single label were 
preferentially assigned. 
 
Association with other phenotypes 
To determine if the sentinel AF risk variants had associations with other phenotypes, two 
sources of data were used: 
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1) GWAS catalog. We queried the NHGRI-EBI Catalog of published genome-wide association 
studies73,74 (accessed 2017-08-31) to detect associations of AF risk variants with other 
phenotypes. 
2) UK Biobank phenome-wide association study (PheWAS). A PheWAS was conducted in 
the UK Biobank in European ancestry individuals. Ancestry definition and sample QC exclusions 
were performed in the same manner as for the primary statistical analysis, as described above. 
We further removed one sample for each pair of second degree or closer relatives (kinship 
coefficient >0.0884), preferentially keeping the sample with case status or non-missing 
phenotype. We included the following phenotypes: height, body mass index (BMI), smoking, 
hypertension, heart failure, stroke, mitral regurgitation, bradyarrhythmia, peripheral vascular 
disease (PVD), hypercholesterolemia, coronary artery disease (CAD), and type II diabetes. 
Phenotype definitions are shown in Supplementary Table 21. Number of samples analyzed, as 
well as case and referent counts for each phenotype are listed in Supplementary Table 22. 
Binary phenotypes were analyzed with a logistic regression model and quantitative phenotypes 
with a linear regression model using imputed genotype dosages in PLINK 2.00.44 As covariates 
we included sex, age at first visit, genotyping array, and the first 10 principal components.  
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Proportion of heritability explained 
We calculated SNP-heritability (h2g) of AF-associated loci with the REML algorithm in BOLT-
LMM v2.275 in 120,286 unrelated samples of European ancestry from a subset of the UK 
Biobank dataset comprising a prior interim release as previously described in separate work 
from our group.10 We defined loci based on a 1MB (+/- 500kb) window around 84 sentinel 
variants from the European ancestry meta-analysis. We transformed the h2g estimates into 
liability scale (AF prevalence = 2.45% in UK Biobank). We then calculated the proportion of h2g 
explained at AF loci by dividing the h2g estimate of AF-associated loci by the total h2g for AF, that 
was based on 811,488 LD-pruned and hard-called common variants (MAF ≥1%).10 
 
Life Sciences Reporting Summary 
Further information on experimental design is available in the Life Sciences Reporting 
Summary. 
 
Data Availability and Accession Code Availability 
The datasets generated during and/or analyzed during the current study are available from the 
corresponding author upon reasonable request. The results of this study are available on the 
Cardiovascular Disease Knowledge Portal (http://www.broadcvdi.org/). The left atrial RNA-
sequencing data can be accessed via dbGaP under the accession number phs001539. 
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